Sudan Loganathan
Stock Analyst at Stephens & Co.
(1.98)
# 2,071
Out of 4,502 analysts
9
Total ratings
42.86%
Success rate
-2.36%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Reiterates: Overweight | $5 | $0.68 | +636.70% | 2 | May 24, 2024 | |
| EXEL Exelixis | Initiates: Equal-Weight | $23 | $22.96 | +0.17% | 1 | May 14, 2024 | |
| ELEV Elevation Oncology | Initiates: Overweight | $8 | $2.89 | +176.82% | 1 | May 14, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Overweight | $20 | $21.04 | -4.94% | 1 | May 14, 2024 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $20 | $10.95 | +82.65% | 1 | May 14, 2024 | |
| BPMC Blueprint Medicines | Initiates: Overweight | $140 | $113.69 | +23.14% | 1 | May 14, 2024 | |
| ATNM Actinium Pharmaceuticals | Initiates: Overweight | $25 | $7.90 | +216.46% | 1 | May 14, 2024 | |
| DCTH Delcath Systems | Initiates: Overweight | $25 | $8.70 | +187.36% | 1 | May 14, 2024 |
Sensei Biotherapeutics
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.68
Upside: +636.70%
Exelixis
May 14, 2024
Initiates: Equal-Weight
Price Target: $23
Current: $22.96
Upside: +0.17%
Elevation Oncology
May 14, 2024
Initiates: Overweight
Price Target: $8
Current: $2.89
Upside: +176.82%
Nurix Therapeutics
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $21.04
Upside: -4.94%
Inovio Pharmaceuticals
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $10.95
Upside: +82.65%
Blueprint Medicines
May 14, 2024
Initiates: Overweight
Price Target: $140
Current: $113.69
Upside: +23.14%
Actinium Pharmaceuticals
May 14, 2024
Initiates: Overweight
Price Target: $25
Current: $7.90
Upside: +216.46%
Delcath Systems
May 14, 2024
Initiates: Overweight
Price Target: $25
Current: $8.70
Upside: +187.36%